February 2025 in “FASEB BioAdvances” Verteporfin reduces growth and stem cell traits in rat hair follicle cells by blocking the Hippo pathway.
July 2025 in “Journal of Dermatology Research and Therapy” The study explores the use of verteporfin, an FDA-approved drug for wet macular degeneration, to promote hair regrowth and reduce fibrosis after hair transplantation. A 27-year-old female underwent a hair transplant with 1,000 grafts, receiving verteporfin treatment on one side of the incision. After 8 weeks, the treated side showed increased hair density (20x21 mm) compared to the control side (12x16 mm), with similar hair texture. The findings suggest verteporfin's potential in enhancing cosmetic and functional recovery post-transplant, warranting further research.
July 2021 in “Plastic and reconstructive surgery. Global open” Verteporfin treatment in mice led to complete skin healing without scarring.
13 citations,
February 2019 in “Türk oftalmoloji dergisi” New treatments for chronic central serous chorioretinopathy show promise in preventing permanent vision loss.
15 citations,
April 2016 in “Eye” Finasteride effectively treats central serous chorioretinopathy.